MRNA Moderna
Queued for filing review — no Filing Score exists before its 10-K is processed, and no number is shown that the pipeline has not computed. The business-quality screen and the statement series below are deterministic reads of the filed XBRL.
Business quality — Buffett/Munger screen DETERMINISTIC · COMPUTED FROM THE STATEMENTS · NOT A SCORE
| Measure | Latest | Reading |
|---|---|---|
| Return on equity | -28.9% | weak |
| Share count, year-end | +2.1% | diluting |
| Debt to equity | 0.07 | low |
| FCF consistency, 5yr | positive 2 of 5 | volatile |
| Margin stability | pre-tax margin -142.4% | volatile |
Statement series EACH OPENS ITS OWN FIVE-YEAR PAGE
| Measure | Latest | Year |
|---|---|---|
| Revenue | $1.9B | FY2025 |
| Net income | −$2.8B | FY2025 |
| Operating cash flow | −$1.9B | FY2025 |
| Free cash flow | −$2.1B | FY2025 |
| Capital expenditure | $192M | FY2025 |
| Cash & equivalents | $2.6B | FY2025 |
| Total assets | $12.3B | FY2025 |
| Shareholders' equity | $8.7B | FY2025 |
| Return on equity | -28.9% | FY2025 |
| Days sales outstanding | 34.5 days | FY2025 |
Not investment advice. Scores grade filings, not companies, and exist only for filings actually reviewed; this name carries no number until then.